LEADER 01417nas  22004453a 450 
001 996417424303316
005 20240620223535.0
011   $a1473-1568
035   $a(CKB)110978984568021
035   $a(CONSER)sn-98039390-
035   $a(EXLCZ)99110978984568021
100   $a19980910a19979999  ---         -
101 0 $aeng
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aCancer drug news
210   $aChichester, West Sussex, U.K. $cEspicom Business Intell[i]gence
215   $a1 online resource
311 08$aPrint version: Cancer drug news. 1369-7129 (DLC)sn-98039390- (OCoLC)39933686 
606   $aCancer$xChemotherapy$vPeriodicals
606   $aAntineoplastic agents$vPeriodicals
606   $aAntineoplastic Agents
606   $aClinical Trials as Topic
606   $aAntineoplastic agents$2fast$3(OCoLC)fst00810595
606   $aCancer$xChemotherapy$2fast$3(OCoLC)fst00845327
608   $aPeriodical
608   $aPeriodicals.$2fast
608   $aPeriodicals.$2lcgft
615  0$aCancer$xChemotherapy
615  0$aAntineoplastic agents
615 02$aAntineoplastic Agents
615 02$aClinical Trials as Topic
615  7$aAntineoplastic agents.
615  7$aCancer$xChemotherapy.
906   $aJOURNAL
912   $a996417424303316
920   $aexl_impl conversion
996   $aCancer drug news$92579376
997   $aUNISA